Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease

被引:14
作者
Ishibashi, Kenji [1 ,2 ]
Miura, Yoshiharu [2 ]
Wagatsuma, Kei [1 ,3 ]
Toyohara, Jun [1 ]
Ishiwata, Kiichi [1 ,4 ,5 ]
Ishii, Kenji [1 ]
机构
[1] Tokyo Metropolitan Inst Gerontol, Res Team Neuroimaging, Tokyo, Japan
[2] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Neurol, Tokyo, Japan
[3] Kitasato Univ, Sch Allied Hlth Sci, Sagamihara, Kanagawa, Japan
[4] Southern Tohoku Res Inst Neurosci, Inst Cyclotron & Drug Discovery Res, Koriyama, Fukushima, Japan
[5] Fukushima Med Univ, Dept Biofunct Imaging, Fukushima, Japan
关键词
adenosine A(2A) receptor; coffee; caffeine; Parkinson's disease; C-11-preladenant PET; REFERENCE TISSUE MODEL; HUMAN BRAIN; PET; RISK;
D O I
10.1002/mds.28897
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Coffee intake can decrease the risk for Parkinson's disease (PD). Its beneficial effects are allegedly mediated by caffeine through adenosine A(2A) receptor (A(2A)R) antagonist action. Objective We aimed to calculate occupancy rates of striatal A(2A)Rs by caffeine after coffee intake in PD. Methods Five patients with PD underwent C-11-preladenant positron emission tomography scanning at baseline and after intake of coffee containing 129.5 mg (n = 3) or 259 mg (n = 2) of caffeine. Concurrently, serum caffeine levels were measured. Results The mean serum caffeine level (mu g/mL) was 0.374 at baseline and increased to 4.48 and 8.92 by 129.5 and 259 mg of caffeine, respectively. The mean occupancy rates of striatal A(2A)Rs by 129.5 and 259 mg of caffeine were 54.2% and 65.1%, respectively. Conclusions A sufficient A(2A)R occupancy can be obtained by drinking a cup of coffee, which is equivalent to approximately 100 mg of caffeine. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
引用
收藏
页码:853 / 857
页数:5
相关论文
共 22 条
[1]   The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease [J].
Chen, Jiang-Fan ;
Cunha, Rodrigo A. .
PURINERGIC SIGNALLING, 2020, 16 (02) :167-174
[2]   Cognitive Enhancers (Nootropics). Part 1: Drugs interacting with Receptors. Update 2014 [J].
Froestl, Wolfgang ;
Muhs, Andreas ;
Pfeifer, Andrea .
JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 (04) :961-1019
[3]   A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease [J].
Hernán, MA ;
Takkouche, B ;
Caamaño-Isorna, F ;
Gestal-Otero, JJ .
ANNALS OF NEUROLOGY, 2002, 52 (03) :276-284
[4]   Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease [J].
Ishibashi, Kenji ;
Miura, Yoshiharu ;
Wagatsuma, Kei ;
Toyohara, Jun ;
Ishiwata, Kiichi ;
Ishii, Kenji .
MOVEMENT DISORDERS, 2021, 36 (01) :268-269
[5]   Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C-preladenant PET [J].
Ishibashi, Kenji ;
Miura, Yoshiharu ;
Wagatsuma, Kei ;
Toyohara, Jun ;
Ishiwata, Kiichi ;
Ishii, Kenji .
NEUROPHARMACOLOGY, 2018, 143 :106-112
[6]   High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine:: A positron emission tomography study using [11C]SA4503 [J].
Ishikawa, Masatomo ;
Ishiwata, Kiichi ;
Ishii, Kenji ;
Kimura, Yuichi ;
Sakata, Muneyuki ;
Naganawa, Mika ;
Oda, Keiichi ;
Miyatake, Ryousuke ;
Fujisaki, Mihisa ;
Shimizu, Eiji ;
Shirayama, Yukihiko ;
Iyo, Masaomi ;
Hashimoto, Kenji .
BIOLOGICAL PSYCHIATRY, 2007, 62 (08) :878-883
[7]   The D-2 receptor occupancy profile of loxapine determined using PET [J].
Kapur, S ;
Zipursky, RB ;
Jones, C ;
Remington, GJ ;
Wilson, AA ;
DaSilva, J ;
Houle, S .
NEUROPSYCHOPHARMACOLOGY, 1996, 15 (06) :562-566
[8]  
Kase Hiroshi, 2003, Neurology, V61, pS97
[9]   Simplified reference tissue model for PET receptor studies [J].
Lammertsma, AA ;
Hume, SP .
NEUROIMAGE, 1996, 4 (03) :153-158
[10]   Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease [J].
Mizuno, Yoshikuni ;
Kondo, Tomoyoshi .
MOVEMENT DISORDERS, 2013, 28 (08) :1138-1141